Point72 Hong Kong LTD Kinnate Biopharma Inc. Transaction History

Point72 Hong Kong LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$9.86 - $15.76 $2,445 - $3,908	248 New	248 $3,000
Q4 2021 Feb 14, 2022	SELL	$16.5 - $25.48 $30,723 - $47,443	-1,862 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$17.81 - $24.87 $33,162 - $46,307	1,862 New	1,862 $43,000
Q1 2021 May 17, 2021	SELL	$26.99 - $40.0 $147,446 - $218,520	-5,463 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$36.35 - $45.25 $198,580 - $247,200	5,463 New	5,463 $217,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.